Edward Tenthoff
Stock Analyst at Piper Sandler
(3.33)
# 987
Out of 5,152 analysts
194
Total ratings
42.41%
Success rate
4.47%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Reiterates: Overweight | $7 → $12 | $8.57 | +40.02% | 1 | Mar 4, 2026 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $10 → $6 | $1.89 | +218.30% | 1 | Feb 25, 2026 | |
| ARVN Arvinas | Reiterates: Overweight | $16 → $20 | $13.49 | +48.26% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Overweight | $63 → $69 | $52.29 | +31.96% | 14 | Feb 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.55 | +56.86% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $17.71 | +108.98% | 4 | Jan 14, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $100 → $110 | $59.66 | +84.38% | 14 | Jan 13, 2026 | |
| ACRV Acrivon Therapeutics | Maintains: Overweight | $6 → $8 | $1.55 | +416.13% | 1 | Jan 9, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $28.09 | +60.23% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $83.07 | +50.48% | 5 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 → $23 | $8.11 | +183.60% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 → $6 | $1.75 | +243.84% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $449 → $489 | $320.56 | +52.55% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $8.80 | +36.36% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.15 | +189.16% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $13.27 | +13.05% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $56.01 | +87.47% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $25.55 | -21.72% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.39 | +405.42% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $14.87 | +222.80% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.88 | +51.18% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $19.00 | +310.53% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $11.28 | +165.96% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $2.29 | +2,738.43% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.73 | +2,639.73% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.18 | +155.32% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.30 | +900.67% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.32 | +354.55% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.58 | +216.46% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.69 | +2,339.02% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $9.15 | +1,867.21% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.80 | +161.90% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $5.20 | +611.54% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $6.40 | +183,149,900.00% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $721.65 | -50.95% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $455.79 | -29.13% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.16 | +146.06% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $41.49 | -13.23% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.37 | +1,722.82% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.59 | +25,135.53% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.33 | +4,246,053.85% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $759.80 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $12.93 | +8,128.92% | 2 | Apr 15, 2013 |
ImmunityBio
Mar 4, 2026
Reiterates: Overweight
Price Target: $7 → $12
Current: $8.57
Upside: +40.02%
Cardiff Oncology
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $6
Current: $1.89
Upside: +218.30%
Arvinas
Feb 25, 2026
Reiterates: Overweight
Price Target: $16 → $20
Current: $13.49
Upside: +48.26%
Moderna
Feb 23, 2026
Maintains: Overweight
Price Target: $63 → $69
Current: $52.29
Upside: +31.96%
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.55
Upside: +56.86%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $17.71
Upside: +108.98%
Arrowhead Pharmaceuticals
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $59.66
Upside: +84.38%
Acrivon Therapeutics
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.55
Upside: +416.13%
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $28.09
Upside: +60.23%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $83.07
Upside: +50.48%
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $8.11
Upside: +183.60%
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.75
Upside: +243.84%
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $320.56
Upside: +52.55%
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $8.80
Upside: +36.36%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.15
Upside: +189.16%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $13.27
Upside: +13.05%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $56.01
Upside: +87.47%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $25.55
Upside: -21.72%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.39
Upside: +405.42%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $14.87
Upside: +222.80%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.88
Upside: +51.18%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $19.00
Upside: +310.53%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $11.28
Upside: +165.96%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $2.29
Upside: +2,738.43%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.73
Upside: +2,639.73%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.18
Upside: +155.32%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.30
Upside: +900.67%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.32
Upside: +354.55%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.58
Upside: +216.46%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.69
Upside: +2,339.02%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $9.15
Upside: +1,867.21%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.80
Upside: +161.90%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $5.20
Upside: +611.54%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $6.40
Upside: +183,149,900.00%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $721.65
Upside: -50.95%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $455.79
Upside: -29.13%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.16
Upside: +146.06%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $41.49
Upside: -13.23%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.37
Upside: +1,722.82%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.59
Upside: +25,135.53%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.33
Upside: +4,246,053.85%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $759.80
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $12.93
Upside: +8,128.92%